Drug Trial Radar · NCT01423188
The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
Last checked: Nov 19, 2026Latest source record: Sep 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
176
Actual
Start
Aug 2011
Primary completion
Jun 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- Resverlogix CorpIndustry
- Sponsor type
- Industry
- Collaborators
- The Cleveland Clinic
- First posted
- Aug 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to provide an assessment of the change in baseline lipid parameters with RVX000222 after 12 weeks and 24 weeks of treatment when given in addition to optimized statin background therapy in subjects with low baseline HDL-C.
Conditions
- Coronary Artery Disease
- Dyslipidemia
Interventions
RVX000222Drug
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks
Placebo RVX000222Drug
capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percent change in HDL-C from baseline to 24 weeks for RVX000222 200 mg daily compared to placeboTime frame: 24 weeks
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Bloemfontein, South Africa
Site not named
Cape Town, South Africa
Site not named
Cape Town, South Africa
Site not named
Johannesburg, South Africa
Site not named
Western Cape, South Africa
Site not named
East Burger Street, Bloemfontein, South Africa
Site not named
Westdene, Bloemfontein, South Africa
Site not named
Goodwood, Cape Town, South Africa
Site not named
Kraaifontein, Cape Town, South Africa
Site not named
Pinelands, Cape Town, South Africa
Site not named
Chatsworth, Durban, South Africa
Site not named
KwaKhangela, Durban, South Africa
Site not named
Merebank, Durban, South Africa
Site not named
Sydenham, Durban, South Africa
Site not named
Tongaat, Durban, South Africa
Site not named
Umhlanga, Durban, South Africa
Site not named
Lenasia, Johannesburg, South Africa
Site not named
Halfway House, Midrand, South Africa
Site not named
Die Wilgers, Pretoria, South Africa
Site not named
Eloffsdal, Pretoria, South Africa
Site not named
Kuils River, Western Cape, South Africa
Site not named
Parow, Western Cape, South Africa
Site not named
Somerset West, Western Cape, South Africa
Site not named
Stellenbosch, Western Cape, South Africa
Site not named
Worcester, Western Cape, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.